EcoDrugPlus

Neuropeptide Y Receptor Type 4-2

Ensembl ID : ENSPSNG00000011938
Gene Symbol: LOC116741714
2 Cross references
116 Possible Orthologues:

Neurotensin Receptor 1

Ensembl ID : ENSPSNG00000021395
Gene Symbol: NTSR1
3 Cross references
211 Possible Orthologues:

Neurotrophic Receptor Tyrosine Kinase 1

Ensembl ID : ENSPSNG00000003021
Gene Symbol: NTRK1
3 Cross references
199 Possible Orthologues:

Neurotrophic Receptor Tyrosine Kinase 2

Ensembl ID : ENSPSNG00000001580
Gene Symbol: NTRK2
1 Cross references
286 Possible Orthologues:

Neurotrophic Receptor Tyrosine Kinase 3

Ensembl ID : ENSPSNG00000003612
Gene Symbol: NTRK3
3 Cross references
269 Possible Orthologues:

Nicastrin

Ensembl ID : ENSPSNG00000006871
Gene Symbol: NCSTN
3 Cross references
203 Possible Orthologues:

Nicotinamide Phosphoribosyltransferase

Ensembl ID : ENSPSNG00000022594
Gene Symbol: NAMPT
3 Cross references
235 Possible Orthologues:

Nischarin

Ensembl ID : ENSPSNG00000005940
Gene Symbol: NISCH
2 Cross references
209 Possible Orthologues:

Nitric Oxide Synthase 2

Ensembl ID : ENSPSNG00000020021
Gene Symbol: NOS2
1 Cross references
163 Possible Orthologues:

Notch Receptor 1

Ensembl ID : ENSPSNG00000002953
Gene Symbol: NOTCH1
3 Cross references
273 Possible Orthologues:

Notch Receptor 3

Ensembl ID : ENSPSNG00000002628
Gene Symbol: NOTCH3
3 Cross references
200 Possible Orthologues:

Nuclear Factor Kappa B Subunit 1

Ensembl ID : ENSPSNG00000016882
Gene Symbol: NFKB1
3 Cross references
200 Possible Orthologues:

Select Keywords:


PREMIER has received funding from the Innovative Medicines Initiative 2 Joint Undertaking (JU) under grant agreement No 875508. The JU receives support from the EU’s Horizon 2020 research and innovation programme and the European Federation of Pharmaceutical Industries and Associations (EFPIA). The views reflect only the authors’ perspective and the JU is not responsible for any use that may be made of the information this manuscript contains. Elements of the website have been developed under projects from the Biocenter Finland Drug Discovery and Chemical Biology network. CSC-IT is thanked for providing computational resources. Content of the website is provided without guarantee for correctness. Data has been collected and integrated from multiple public sources, for the largest: FDA, HUGO Gene Nomenclature Committee, ChEMBL, IUPHAR/BPS guide to pharmacology, Reactome, UniProt, and Ensembl. Credit is given to Ensembl for collecting species images (provided under public domain licences such as Wikimedia and NHGRI).

PREMIER has received funding from the Innovative Medicines Initiative 2 Joint Undertaking (JU) under grant agreement No 875508. The JU receives support from the EU’s Horizon 2020 research and innovation programme and the European Federation of Pharmaceutical Industries and Associations (EFPIA). The views reflect only the authors’ perspective and the JU is not responsible for any use that may be made of the information this manuscript contains.

Elements of the website have been developed under projects from the Biocenter Finland Drug Discovery and Chemical Biology network. CSC-IT is thanked for providing computational resources. Content of the website is provided without guarantee for correctness. Data has been collected and integrated from multiple public sources, for the largest: FDA, HUGO Gene Nomenclature Committee, ChEMBL, IUPHAR/BPS guide to pharmacology, Reactome, UniProt, and Ensembl. Credit is given to Ensembl for collecting species images (provided under public domain licences such as Wikimedia and NHGRI).